Regulation - Pharmaceutical, Genito-urinary

Filter

Popular Filters

Netherlands first to approve Astellas' Vesomni

23-05-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says that the Dutch Medicines…

Astellas PharmaEuropeGenito-urinaryPharmaceuticalRegulationVesomni

FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine

21-01-2013

US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

Astellas' Betmiga Oked in EU for overactive bladder

14-01-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has received approval from…

Astellas PharmaBetmigaEuropeGenito-urinarymirabegronPharmaceuticalRegulation

PDUFA Action Date for Astellas enzalutamide; Urogenix facility to close

07-08-2012

The US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date…

Astellas PharmaenzalutamideGenito-urinaryMedivationOncologyPharmaceuticalRegulationResearchUrogenixVaccines

FDA approves Astellas' Myrbetriq for overactive bladder

02-07-2012

The US Food and Drug Administration has approved Japanese drug major Astellas Pharma's (TYO: 4503) Myrbetriq…

Astellas PharmaGenito-urinarymirabegronMyrbetriqNorth AmericaPharmaceuticalRegulation

FDA advisory panel backs Astellas OAB drug mirabegron

10-04-2012

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) said last week that the Reproductive…

Genito-urinarymirabegronNorth AmericaPharmaceuticalRegulation

Botox shows efficacy in idiopathic overactive bladder, says Allergan

29-03-2012

USA-based Allergan (NYSE: AGN) announced that two Phase III clinical trials of Botox (onabotulinumtoxinA),…

AllerganBotoxGenito-urinaryPharmaceuticalRegulationResearch

Overactive bladder gel gets FDA nod

09-12-2011

The US Food and Drug Administration (FDA) has approved US drugmaker Antares Pharma’s (NYSE Amex:…

Antares PharmaGenito-urinaryNorth AmericaOxybutyninPharmaceuticalRegulationWatson Pharmaceuticals

Company Spotlight

ImmunoGen

ImmunoGen

Back to top